Hydroxyurea is an oral chemotherapy medication that is used as a “cytoreductive therapy” in myeloproliferative neoplasms (MPNs) to control the number of blood white cells, red cells, platelets, and to reduce spleen size, and phlebotomy requirements. Hydroxyurea works by inhibiting DNA synthesis and causing cell death. Hydroxyurea can cause white and red blood cells and platelets to decrease below normal values and this can increase the risk of infection, anemia, and/or bleeding. Hydroxyurea also goes by brand names Hydrea® and Droxia®.
In clinical trials, hydroxyurea has been shown to reduce the risk of abnormal blood clots in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Hydroxyurea is often used in older, higher-risk patients in order to decrease the risk of thrombosis (blood clots). During treatment with hydroxyurea, routine blood work will be done to monitor side effects and response to therapy. You should report to your medical team any side effect you think you may be experiencing.
Common side effects:
Potentially Serious Side Effects:
Additional Information: https://medlineplus.gov/druginfo/meds/a682004.html